KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationCost Of RevenueCustomer Additions AnnualCustomers Count AnnualDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome (Loss) Before Income Taxes By RegionLong Lived AssetsNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNo. Of Genes ShippedNo. Of Genes Shipped AnnualNo. Of Orders TotalNo. Of Orders Total AnnualNo. Of ShipmentsOpex As A % Of Total Revenue %OPEX SegregationOrder BreakdownProperty And Equipment, Net BreakdownRevenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By IndustryRevenue By Industry %Revenue By Industry AnnualRevenue By Industry Annual %Revenue By ProductRevenue By Product %Revenue By Product AnnualRevenue By Product Annual %Revenue Mix From Repeat Customers %Shipped ProductsValue Of Orders
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) Cost Of Revenue (2018 - 2025)

Twist Bioscience (TWST) has disclosed Cost of Revenue for 6 consecutive years, with $42.4 million as the latest value for Q3 2023.

  • On a quarterly basis, Cost of Revenue rose 34.31% to $42.4 million in Q3 2023 year-over-year; TTM through Sep 2023 was $155.4 million, a 30.21% increase, with the full-year FY2025 number at $185.6 million, up 3.31% from a year prior.
  • Cost of Revenue was $42.4 million for Q3 2023 at Twist Bioscience, up from $41.8 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $42.4 million in Q3 2023 to a low of $11.4 million in Q2 2019.
  • A 5-year average of $23.8 million and a median of $20.9 million in 2021 define the central range for Cost of Revenue.
  • Biggest YoY gain for Cost of Revenue was 56.16% in 2022; the steepest drop was 8.82% in 2022.
  • Twist Bioscience's Cost of Revenue stood at $13.8 million in 2019, then soared by 31.69% to $18.2 million in 2020, then surged by 48.97% to $27.1 million in 2021, then rose by 8.82% to $29.4 million in 2022, then skyrocketed by 44.09% to $42.4 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Cost of Revenue are $42.4 million (Q3 2023), $41.8 million (Q2 2023), and $41.7 million (Q1 2023).